Clinical Trials
Teclistamab With Daratumumab Linked to Better PFS and OS vs Standard PI Regimens
Anderson et alAdvances in Therapy

In the phase 3 MajesTEC-3 trial (NCT05083169), teclistamab combined with daratumumab (Tec-Dara) significantly improved progression-free survival (PFS) and overall survival (OS) compared to investigator's choice of daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/bortezomib/dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM) after 1 to 3 prior lines of therapy. Among comparator-arm patients, 85.5% (253/296) were refractory to an immunomodulatory drug (IMiD); 90.7% (263/290) received IMiD-based DPd and 9.3% (27/290) received proteasome inhibitor (PI)-based DVd.
To evaluate Tec-Dara against standard PI-based combinations, researchers conducted an inverse probability of treatment weighting (IPTW) analysis utilizing individual patient-level data from MajesTEC-3, the CANDOR trial (NCT03158688; daratumumab/carfilzomib/dexamethasone [DKd]), and the CASTOR trial (NCT02136134; DVd). Following weighting adjustment, baseline patient characteristics were well balanced across the study cohorts.
Tec-Dara was significantly associated with prolonged PFS compared with DKd (HR 0.22; 95% CI 0.15–0.33; P < 0.001) and DVd (HR 0.11; 95% CI 0.07–0.17; P < 0.001). Tec-Dara was also significantly associated with prolonged OS versus DKd (HR 0.40; 95% CI 0.26–0.61; P < 0.001) and DVd (HR 0.24; 95% CI 0.14–0.40; P < 0.001). Additionally, patients demonstrated higher overall response rates (ORR RR 1.11 vs DKd; RR 1.10 vs DVd), very good partial response or better (≥VGPR RR 1.33 vs DKd; RR 2.20 vs DVd), and complete response or better (≥CR RR 2.84 vs DKd; RR 5.17 vs DVd). The authors conclude these results demonstrate consistent survival benefits and deeper responses, supporting Tec-Dara as a new standard-of-care regimen for RRMM as early as the second line.
Key Takeaways
- Tec-Dara was significantly associated with reduced risk of progression or death compared with DKd (HR 0.22; 95% CI 0.15–0.33; P < 0.001) and DVd (HR 0.11; 95% CI 0.07–0.17; P < 0.001).
- Overall survival was significantly improved with Tec-Dara compared with DKd (HR 0.40; 95% CI 0.26–0.61; P < 0.001) and DVd (HR 0.24; 95% CI 0.14–0.40; P < 0.001).
- Patients receiving Tec-Dara achieved higher complete response or better rates compared with DKd (RR 2.84) and DVd (RR 5.17).
Read the original sourceAdvances in Therapy
